Glycosaminoglycan-peptide complex in the treatment of knee and hip osteoarthritis: from the past to the future
https://doi.org/10.14412/1995-4484-2020-91-96
Abstract
The glycosaminoglycan-peptide complex (GPC) Rumalon is a popular injectable drug used to treat osteoarthritis (OA). GPC was one of the world’s first drugs designed for the pharmacotherapy of this disease. The drug has been rigorously tested for efficacy and safety in a series of international placebo-controlled randomized trials. Most of them showed the good therapeutic potential of GPC. Several open-labelled studies have recently been underway in Russia, confirming the ability of GPC to significantly reduce the intensity of pain and to improve function in patients with knee OA and chronic nonspecific back pain. All investigations of GPC demonstrated its good tolerance and the absence of serious complications, as well as when this medication was used for a long time.
About the Author
A. E. Karateev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests: not
Russian Federation
Andrey Karateev
34A, Kashirskoe Shosse, Moscow 115522Competing Interests: not
References
1. Alekseeva LI, Taskina EA, Kashevarova NG. Osteoarthritis: epidemiology, classification, risk factors, and progression, clinical presentation, diagnosis, and treatment. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2019;13(2):9-21 (In Russ.). doi: 10.14412/1996-7012-2019-2-9-21
2. Henrotin Y, Marty M, Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? Maturitas. 2014 Jul;78(3):184-7. doi: 10.1016/j.maturitas.2014.04.015. Epub 2014 May 1.
3. DiNubile N. Glucosamine and Chondroitin Sulfate: What Has Been Learned Since the Glucosamine/chondroitin Arthritis Intervention Trial. Orthopedics. 2018 Jul 1;41(4):200-7. doi: 10.3928/01477447-20180511-06. Epub 2018 May 18.
4. Wagenhaeuser FJ, Jasinski B, Weigel W. The action of Rumalon, an extract of cartilage and bone marrow: experimental and clinical investigation. Arch Interam Rheumatol. 1963 Dec;6:463-78.
5. Nasonova VA. Diagnosis and treatment of elderly patients suffering from manifest osteoarthrosis. RusskiiMeditsinskiiZhurnal. 2001;(3):157-62 (In Russ.).
6. Klein R, Becker EW, Berg PA, Bernau A. Immunomodulatory properties of rumalon, a glycosaminoglycan peptide complex, in patients with osteoarthritis: activation of T helper cell type 2 cytokines and antigen-specific IgG4 antigen-specific igG4 antibodies. JRheumatol. 2000 Feb;27(2):448-54.
7. Dean D, Muniz O, Rodriquez I, et al. Amelioration of lapine osteoarthritis by treatment with glycosaminoglycan-peptide association complex (Rumalon). Arthritis Rheum. 1991;34:304-13. doi: 10.1002/art.1780340308
8. Vignon E, Martin A, Mathieu P, et al. Study of the effect of a gly-cosaminoglycan-peptide complex on the degradative enzyme activities in human osteoarthritic cartilage. Clin Rheumatol. 1990 Sep;9(3):383-8. doi: 10.1007/BF02114400
9. Bouakka M, Loyau G, Bocquet J. Effect of a glycosaminoglycan-peptide complex on the biosynthesis of protoglycans in articular chondrocytes treated with interleukin-1. Curr Ther Res. 1988;43:588-99.
10. Annefeld M, Erne B. The mode of action of a glycosaminoglycan-peptide-complex (Rumalon) on articular cartilage of the rat in vivo. Clin Rheumatol. 1987 Sep;6(3):340-9. doi: 10.1007/BF02206832
11. Altman RD. Measurement of structure (disease) modification in osteoarthritis. Osteoarthritis Cartilage. 2004;12 Suppl A:S69-76. doi: 10.1016/j.joca.2003.09.011
12. Adler E, Wolf E, Taustein I. A double blind trial with cartilage and bone marrow extract in degenerative gonarthrosis. Scand J Rheumatol. 1987;16(1):6-11. doi: 10.3109/03009747009165349
13. Katona G. A clinical trial of glycosaminoglycan-peptide complex ('Rumalon') in patients with osteoarthritis of the knee. Curr Med Res Opin. 1987;10(9):625-33. doi: 10.1185/03007998709112416
14. Gramajo RJ, Cutroneo EJ, Fernandez DE, et al. A single-blind, placebo-controlled study of glycosaminoglycan-peptide complex ('Rumalon') in patients with osteoarthritis of the hip or knee. Curr Med Res Opin. 1989;11(6):366-73. doi: 10.1185/03007998909110137
15. Rejholec V, Kralova M. Langzeitbehandlung der Coxarthrose mit Rumalon®. Akt Rheumatol. 1984;9:139-48. doi: 10.1055/s-2008-1048133
16. Pavelka K, Gatterova J, Gollerova V, et al. A 5-year randomized controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon) as a structure modifying therapy in osteoarthritis of the hip and knee. Osteoarthritis Cartilage. 2000 Sep;8(5):335-42. doi: 10.1053/joca.1999.0307
17. Alekseeva LI, Karyakin AN, Smirnov AV, Benevolenskaya LI. Primenenie Rumalona pri gonartroze. Terapevticheskii Arkhiv. 1997;(5):64-6 (In Russ.).
18. Алексеева ЛИ, Бельская ГН, Каракулова ЮВ и др. Возможности патогенетического лечения хронической боли в спине. Manage Pain. 2018;(2):3-7 [Alekseeva LI, Bel'skaya GN, Karakulova YuV, et al. The possibilities of the pathogenetic treatment of chronic back pain. Manage Pain. 2018;(2):3-7 (In Russ.)].
19. Naumov AV, Tkacheva ON, Kotovskaya YuV, Khovasova NO. Efficacy and safety of the glycosaminoglycan-peptide complex in the treatment of exacerbations of chronic pain in osteoarthritis of the knee joints in comorbid patients (results of the DARTS observation program). Lechashchii Vrach. 2018;(7):2-7 (In Russ.).
20. Karateev AE, Alekseeva LI, Lila AM, et al. Therapeutic potential of glycosaminoglycan-peptide complex injectable form use in knee osteoarthritis treatment according to PRIMULA (Use of Rumalon with initially small success in the treatment of osteoarthritis) study results: supplemented data. Consilium Medicum. 2018;20(9):51-7 (In Russ.). doi: 10.26442/2075-1753_2018.9.51-57
21. Berg PA, Kaboth U, Becker EW, Klein R. The analysis of a severe side effect of a cartilage-protective agent by immunological studies. Dtsch Med Wochenschr. 1992 Oct 16;117(42):1589-93. doi: 10.1055/s-2008-1062480
22. Du rk H, Haase K, Saal J, et al. Nephrotic syndrome after injections of bovine cartilage and marrow extract. Lancet. 1989 Mar 18;1(8638):614. doi: 10.1016/S0140-6736(89)91636-X
23. Glogner P, Berg PA, Becker EW. Side effects of a cartilage extract. Dtsch Med Wochenschr. 1989 Feb 24;114(8):319.
24. Schacht E, Roetz R. Answer: Nephrotic syndrome after injections of bovine cartilage and marrow extract. Lancet. 1989 Apr 29;1(8644):963. doi: 10.1016/S0140-6736(89)92547-6
Review
For citations:
Karateev A.E. Glycosaminoglycan-peptide complex in the treatment of knee and hip osteoarthritis: from the past to the future. Rheumatology Science and Practice. 2020;58(1):91-96. (In Russ.) https://doi.org/10.14412/1995-4484-2020-91-96
Views:
5642
Email this article 